Interfering with interferon: Re‐igniting the debate on calcineurin inhibitor choice and antiviral therapy for hepatitis C virus recurrence
Koichi Watashi, Herold J. Metselaar, Luc J. W. van der Laan – 27 February 2008
Isolation and characterization of a novel population of progenitor cells from unmanipulated rat liver
M. Behnan Sahin, Robert E. Schwartz, Shannon M. Buckley, Yves Heremans, Lucas Chase, Wei‐Shou Hu, Catherine M. Verfaillie – 27 February 2008 – Widespread use of liver transplantation in the treatment of hepatic diseases is restricted by the limited availability of donated organs. One potential solution to this problem would be isolation and propagation of liver progenitor cells or stem cells. Here, we report on the isolation of a novel progenitor cell population from unmanipulated (that is, no prior exposure to chemicals and no injury) adult rat liver.
Reply:
Zhiping Li – 27 February 2008
Reply:
Dominique Thabut, Khalid Tazi, Dominique Bonnefont‐Rousselot, Richard Moreau, Didier Lebrec – 27 February 2008
Importance of local infection in hepatic artery pseudoaneurysms
Thomas Johnston, Hoonbae Jeon, Roberto Gedaly, Dinesh Ranjan – 27 February 2008
Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma
Soo Hyung Ryu, Young‐Hwa Chung, Hyunseung Lee, Jeong A. Kim, Hyun Deok Shin, Hyun Joo Min, Dong Dae Seo, Myoung Kuk Jang, Eunsil Yu, Kyu‐Won Kim – 27 February 2008 – Metastatic tumor antigen 1 (MTA1) is known to play a role in angiogenic processes as a stabilizer of hypoxia‐inducible factor 1‐α (HIF1‐α). In this study, we examined whether overexpression of MTA1 affects the recurrence of hepatocellular carcinoma (HCC) after surgical resection and the survival of the patients. A total of 506 HCC patients who underwent hepatic resection were included in the study.
Reply:
William M. Lee – 27 February 2008
Monitoring preload during liver transplantation
Andre M. De Wolf, Shushma Aggarwal – 27 February 2008
Removing patients from the liver transplant wait list: A survey of US liver transplant programs
Kevin P. Charpentier, Arun Mavanur – 27 February 2008 – Guidelines are in place regarding who is a candidate for liver transplantation. Once a potential candidate is listed, there are no uniform guidelines indicating when he should be removed from the list because of a change in clinical status. A survey with 14 scenarios was sent to the medical and surgical directors of all liver transplant programs in the United States. In each scenario, clinical information was provided about a patient active on the transplant wait list.
Comparison of histidine‐tryptophan‐ketoglutarate solution and University of Wisconsin solution in extended criteria liver donors
Richard S. Mangus, Jonathon A. Fridell, Rodrigo M. Vianna, Martin A. Milgrom, Paul Chestovich, Ray K. Chihara, A. Joseph Tector – 27 February 2008 – Liver, pancreas, and kidney allografts preserved in histidine‐tryptophan‐ketoglutarate (HTK) and University of Wisconsin (UW) solutions have similar clinical outcomes. This study compares HTK and UW in a large number of standard criteria donor (SCD) and extended criteria donor (ECD) livers at a single center over 5 years.